BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

...pipeline with more deals. Santarelli noted that Therachon itself had acquired apraglutide via its purchase of GLyPharma Therapeutic Inc....
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

...added GLP-2 analog apraglutide, a second clinical program to treat SBS, via its acquisition of GLyPharma Therapeutic Inc....
BioCentury | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

...testing to treat SBS. Therachon had obtained apraglutide in October 2018 via its acquisition of GLyPharma Therapeutic Inc....
Items per page:
1 - 3 of 3
BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

...pipeline with more deals. Santarelli noted that Therachon itself had acquired apraglutide via its purchase of GLyPharma Therapeutic Inc....
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

...added GLP-2 analog apraglutide, a second clinical program to treat SBS, via its acquisition of GLyPharma Therapeutic Inc....
BioCentury | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

...testing to treat SBS. Therachon had obtained apraglutide in October 2018 via its acquisition of GLyPharma Therapeutic Inc....
Items per page:
1 - 3 of 3